Protara Therapeutics (TARA) Drops 3.69% to 2024 Low

Protara Therapeutics (TARA) shares fell 3.69% today, reaching their lowest level since December 2024, with an intraday decline of 4.36%.

The strategy of buying TARA shares after they reached a recent low and holding for 1 week showed poor performance over the past 5 years. The cumulative return was -58.2%, significantly underperforming the market. This indicates that relying on recent price lows as a decision metric and holding for a short duration is not a viable strategy for TARA.

Protara Therapeutics recently raised $100 million through a public offering. This funding is earmarked for clinical trials of its bladder cancer drug, TARA-002, as well as other corporate initiatives. The successful capital raise is expected to bolster the company's financial position and support its ongoing research and development efforts.

Additionally, a buy signal was issued from a pivot bottom point on Monday, June 23, 2025. This technical indicator suggests a potential upward trend in the stock's price, which could have influenced recent trading activity. However, the overall market sentiment and other external factors may also play a role in the stock's performance.